Gmax Biopharm
Hangzhou
About Gmax Biopharm
Gmax Biopharm develops GPCR antibody therapeutics for unmet medical needs in cardiovascular diseases, metabolic disorders, and cancer. Gmax Biopharm develops a proprietary platform with a systemic approach to GPCR MAb generation, screening, and development. Gmax Biopharm enables antibody screening, humanization, and engineering to produce antibody candidates with high drugability and developability.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $78.0M
- Funding stage: Late Stage Venture
- Last round: Series C (Mar 2021)
- Website: gmaxbiopharm.com
- Phone: 86-571-866-33907
Industries & Categories
Biotechnology, Clinical Trials, Health Care, Product Research
Social Profiles
Canonical: https://fsome.com/organization/gmax-biopharm-78009 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.